ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 60 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $91,000 | -48.3% | 44,300 | -5.6% | 0.04% | -37.9% |
| Q4 2021 | $176,000 | -28.2% | 46,931 | -0.9% | 0.07% | -38.9% |
| Q3 2021 | $245,000 | +15.6% | 47,350 | -5.0% | 0.11% | +24.1% |
| Q2 2021 | $212,000 | -45.5% | 49,819 | -32.0% | 0.09% | -47.0% |
| Q1 2021 | $389,000 | +0.3% | 73,237 | +1.8% | 0.16% | +1.9% |
| Q4 2020 | $388,000 | +57.1% | 71,954 | +132.0% | 0.16% | +23.8% |
| Q3 2020 | $247,000 | -30.0% | 31,009 | -12.0% | 0.13% | -22.2% |
| Q2 2020 | $353,000 | +61.9% | 35,241 | -30.4% | 0.17% | -64.0% |
| Q1 2019 | $218,000 | -34.9% | 50,655 | -13.0% | 0.46% | +714.0% |
| Q4 2018 | $335,000 | -34.3% | 58,223 | +54.8% | 0.06% | +7.5% |
| Q3 2018 | $510,000 | -34.1% | 37,603 | -42.3% | 0.05% | -92.3% |
| Q2 2018 | $774,000 | +307.4% | 65,221 | +141.8% | 0.68% | +643.5% |
| Q3 2016 | $190,000 | -13.6% | 26,974 | 0.0% | 0.09% | -43.6% |
| Q2 2016 | $220,000 | -3.9% | 26,974 | -4.3% | 0.16% | -48.3% |
| Q1 2016 | $229,000 | – | 28,182 | – | 0.32% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM ASSET MANAGEMENT LLC | 5,555,461 | $4,405,481 | 2.16% |
| MPM BioImpact LLC | 5,095,912 | $4,041,058 | 0.94% |
| NEA Management Company, LLC | 17,079,778 | $13,544,624 | 0.90% |
| Syncona Portfolio Ltd | 1,377,294 | $1,092,194 | 0.69% |
| PFM Health Sciences, LP | 10,423,135 | $8,265,546 | 0.50% |
| TANG CAPITAL MANAGEMENT LLC | 4,387,238 | $3,479,080 | 0.32% |
| Long Focus Capital Management, LLC | 12,086,915 | $9,584,924 | 0.32% |
| Matrix Capital Management Company, LP | 38,974,185 | $30,906,529 | 0.32% |
| Acuitas Investments, LLC | 479,789 | $380,473 | 0.20% |
| Key Client Fiduciary Advisors, LLC | 336,620 | $266,940 | 0.16% |